Management of idiopathic pulmonary fibrosis.
Publication/Presentation Date
6-1-2011
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing lung disorder characterized by progressive dyspnea, exercise intolerance and, ultimately, respiratory failure and death. The incidence of IPF seems to be increasing, whereas its etiology remains unelucidated. Agents capable of modulating inflammation, kinase pathways, vascular tone, coagulation and fibrosis have been tested in clinical studies although not always in large, randomized, placebo-controlled prospective trials. Despite this effort, a therapy capable of improving survival remains elusive. Consequently, the management of IPF focuses on the early identification of subjects for lung transplantation and on the treatment of comorbidities such as hypoxemia, cough and deconditioning. Until effective therapies are identified, patients and referring physicians are urged to consider participation in well-designed clinical trials.
Volume
341
Issue
6
First Page
450
Last Page
453
ISSN
1538-2990
Published In/Presented At
Fioret, D., Perez, R. L., & Roman, J. (2011). Management of idiopathic pulmonary fibrosis. The American journal of the medical sciences, 341(6), 450–453. https://doi.org/10.1097/MAJ.0b013e31821fbdbc
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
21613933
Department(s)
Administration and Leadership
Document Type
Article